{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis+Brain+Lesion", "query": { "condition": "Multiple Sclerosis Brain Lesion" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis+Brain+Lesion&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T05:59:43.178Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04742400", "title": "Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "tolebrutinib 60mg", "type": "DRUG" }, { "name": "tolebrutinib 120mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 12, "start_date": "2021-04-15", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04742400" }, { "nct_id": "NCT04344626", "title": "Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Epilepsy", "Focal Cortical Dysplasia", "Tuberous Sclerosis", "Hemimegalencephaly", "Polymicrogyria", "Rasmussen Encephalitis", "Sturge-Weber Syndrome", "Gliosis", "Stroke", "Tumor, Brain" ], "interventions": [ { "name": "Intra-operative brain tonometry", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2018-07-16", "completion_date": "2023-03", "has_results": false, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04344626" }, { "nct_id": "NCT02967380", "title": "Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Anaplastic (Malignant) Meningioma", "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Choroid Plexus Neoplasm", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Ependymoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Grade II Meningioma", "Adult Medulloblastoma", "Adult Mixed Glioma", "Adult Oligodendroglioma", "Adult Papillary Meningioma", "Adult Pineal Gland Astrocytoma", "Adult Pineoblastoma", "Adult Primary Melanocytic Lesion of Meninges", "Adult Supratentorial Primitive Neuroectodermal Tumor", "Malignant Adult Intracranial Hemangiopericytoma", "Metastatic Malignant Neoplasm in the Brain", "Multiple Sclerosis", "Recurrent Adult Brain Neoplasm" ], "interventions": [ { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Gadobenate Dimeglumine", "type": "DRUG" }, { "name": "Gadobutrol", "type": "DRUG" }, { "name": "Gadopentetate Dimeglumine", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2011-12-14", "completion_date": "2015-10-14", "has_results": false, "last_update_posted_date": "2017-03-27", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02967380" }, { "nct_id": "NCT00879658", "title": "Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis" ], "interventions": [ { "name": "BAF312", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 297, "start_date": "2009-03-30", "completion_date": "2011-05-04", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 16, "location_summary": "Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Pompano Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00879658" }, { "nct_id": "NCT00676715", "title": "A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Avonex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 220, "start_date": "2008-07-17", "completion_date": "2023-11-08", "has_results": true, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00676715" }, { "nct_id": "NCT00037115", "title": "Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Demyelinating Disorders", "Multiple Sclerosis", "Optic Neuritis", "Myelitis", "Neuritis" ], "interventions": [ { "name": "interferon beta 1a", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 0, "start_date": "2002-05", "completion_date": "2002-12", "has_results": false, "last_update_posted_date": "2018-04-12", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00037115" }, { "nct_id": "NCT02466074", "title": "Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Acetazolamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 5, "start_date": "2016-08-17", "completion_date": "2022-02-07", "has_results": true, "last_update_posted_date": "2023-04-27", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02466074" }, { "nct_id": "NCT00617383", "title": "AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis", "Clinically Isolated Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "10 Years to 45 Years · Female only" }, "enrollment_count": 3, "start_date": "2008-02", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617383" }, { "nct_id": "NCT06322342", "title": "Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System (CNS) Lesions", "Brain Metastases", "Brain Neoplasms", "Brain Neoplasms, Benign", "Brain Tumor, Primary", "Brain Tumor, Recurrent", "Brain Tumors", "Brain Cancer", "Brain Tumor", "Brain Neoplasm, Primary", "Multiple Sclerosis", "Multiple Sclerosis Brain Lesion", "Neurofibroma", "Acoustic Neuroma", "CNS Tumor", "CNS Lesion", "CNS Metastases", "CNS Cancer", "CNS Lymphoma", "Von Hippel Lindau", "Meningioma", "Glioma", "Schwannomas", "Neuroinflammation", "Neoplasia" ], "interventions": [ { "name": "RVP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Reveal Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 18, "start_date": "2024-08-15", "completion_date": "2025-12-19", "has_results": false, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Columbia, Missouri + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06322342" }, { "nct_id": "NCT05359653", "title": "Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Sclerosis (MS)", "Multiple Sclerosis, Relapsing-Remitting", "Multiple Sclerosis, Primary Progressive", "Multiple Sclerosis, Chronic Progressive", "Multiple Sclerosis Relapse", "Multiple Sclerosis Brain Lesion", "Multiple Sclerosis Benign" ], "interventions": [ { "name": "Clemastine Fumarate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 74, "start_date": "2023-08-01", "completion_date": "2026-06-01", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-06-11T05:59:43.178Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05359653" } ] }